Related Experiment Video
Updated: Feb 13, 2026
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
Published on: September 27, 2017
Ruxolitinib Cream As-Needed Monotherapy Demonstrates Sustained Disease and Symptom Control in Patients with Mild to
Andrew Blauvelt1,2, Leon Kircik3,4, Eric L Simpson5
1Oregon Medical Research Center, Portland, OR, USA.
Introduction:
Long-term disease and symptom control is a goal of atopic dermatitis (AD) therapy. This study assessed the long-term maintenance of disease and symptom control with as-needed application of ruxolitinib cream.
Methods:
Patients aged ≥ 12 years with AD, an Investigator's Global Assessment (IGA) score of 2/3, and 3-20% affected body surface area were included in the phase 3 TRuE-AD1 and TRuE-AD2 studies. This analysis included patients randomized to twice-daily (BID) 1.5% ruxolitinib cream for 8 weeks and then as-needed (IGA ≥ 1) BID for up to 44 weeks (long-term safety [LTS] period).
Results:
Among patients evaluated for disease control in the as-needed period (N = 428), IGA 0/1 (skin/almost clear skin) was achieved by 67.1% of patients at week 8. From week 8, 80-90% of patients with IGA 0/1 at a given visit maintained or improved their response at the next visit. Median time to worsening disease (IGA ≥ 2) was 36.1 weeks during the as-needed period, and IGA 0/1 was quickly recaptured. Patients spent a median 43.9% of the as-needed period off treatment due to lesion clearance. No itch/no sleep disturbance (Patient-Oriented Eczema Measure questions 1 and 2) was reported in 32.7%/71.8% of patients at week 8 and 36.2%/74.5% of patients at week 52. No new safety concerns emerged in the LTS period.
Conclusion:
Continued disease and symptom control with substantial time off treatment makes 1.5% ruxolitinib cream an effective long-term option for patients with mild to moderate AD.
Trial Registration:
Clinicaltrials.gov, NCT03745638 and NCT03745651 (studies registered November 19, 2018).
Related Concept Videos
01:43Sustainable Development
01:22Phase-lead and Phase-lag Controllers
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:24Time and frequency -Domain Interpretation of Phase-lead Control
The design of phase-lead control involves the strategic placement of poles and zeros to balance steady-state error and system...
01:21Time and frequency -Domain Interpretation of Phase-lag Control
Phase-lag controllers do not place a pole at zero, but instead influence the steady-state error by amplifying any...